MedTrace Logo

Effect of High-dose Oral Rabeprazole on Recurrent Bleeding After the Endoscopic Treatment of Bleeding Peptic Ulcers

NCT00838682 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 106

Last updated 2010-09-24

Study results available
· View outcomes & findings →

Summary

This study is conducted to compare and evaluate the effect of administering a high-dose intravenous proton pump inhibitors or high-dose oral Rabeprazole in preventing recurrent bleeding after the endoscopic treatment of bleeding peptic ulcers.

Conditions

  • Peptic Ulcer Hemorrhage

Interventions

DRUG

omeprazole sodium IV

Intravenous Omeprazole (brand name: Losec® injection 40 mg) 80 mg as a bolus injection followed by continuous infusion at 8 mg per hour for 3 days. From Day 4, oral Rabeprazole 10 mg once daily for 6 weeks as maintenance therapy.

DRUG

Rabeprazole

Oral Rabeprazole 20 mg twice daily for 3 days. From Day 4, oral Rabeprazole 10 mg once daily for 6 weeks as maintenance therapy.

Sponsors & Collaborators

  • Janssen Korea, Ltd., Korea

    collaborator INDUSTRY

  • The Catholic University of Korea

    lead OTHER

Principal Investigators

  • Hiun-Suk Chae, Professor · The Catholic University of Korea

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
16 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-04-30
Primary Completion
2009-01-31
Completion
2009-03-31

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00838682 on ClinicalTrials.gov